Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches DOI Creative Commons
Mohamed Zaiou, Olivier Joubert

Biomolecules, Journal Year: 2025, Volume and Issue: 15(5), P. 669 - 669

Published: May 5, 2025

Nonalcoholic fatty liver disease (NAFLD) is a growing global health concern, impacting approximately 32.4% of the worldwide population. As linked to metabolic dysfunction, NAFLD continues rise alongside increases in obesity, type 2 diabetes mellitus (T2DM), and syndrome. There considerable evidence indicating that disproportionately affects racial, ethnic, minority groups, although exact reasons for these disparities remain elusive. Contributing factors this may include socioeconomic status, cultural influences, stress, genetic factors, lifestyle choices. Emerging suggests causal could influence epigenetic mechanisms, particularly DNA methylation histone modifications, as well composition diversity gut microbiota. Nevertheless, there scarcity research comprehensively examines interplay between changes microbiome variations relation across different racial ethnic populations globally. This paper intends (i) explore connections NAFLD, disparities, microbiota composition, alterations, while reviewing pertinent studies illustrate how contribute inequities among various groups impacted by disease; (ii) potential therapeutic targets biomarkers advance management NAFLD; (iii) provide insights enhance our understanding mechanisms associated with disease, thereby promoting further field. Advancements area are anticipated susceptibilities at-risk new options its complications.

Language: Английский

Epidemiology of small intestinal bacterial overgrowth DOI Creative Commons

Irina Efremova,

Roman Maslennikov, Elena Poluektova

et al.

World Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 29(22), P. 3400 - 3421

Published: June 6, 2023

Small intestinal bacterial overgrowth (SIBO) is defined as an increase in the content of small intestine above normal values. The presence SIBO detected 33.8% patients with gastroenterological complaints who underwent a breath test, and significantly associated smoking, bloating, abdominal pain, anemia. Proton pump inhibitor therapy significant risk factor for SIBO. increases age does not depend on gender or race. complicates course number diseases may be pathogenetic significance development their symptoms. functional dyspepsia, irritable bowel syndrome, constipation, diarrhea, short chronic pseudo-obstruction, lactase deficiency, diverticular celiac diseases, ulcerative colitis, Crohn's disease, cirrhosis, metabolic-associated fatty liver disease (MAFLD), primary biliary cholangitis, gastroparesis, pancreatitis, cystic fibrosis, gallstone diabetes, hypothyroidism, hyperlipidemia, acromegaly, multiple sclerosis, autism, Parkinson's systemic spondylarthropathy, fibromyalgia, asthma, heart failure, other diseases. often slowdown orocecal transit time that decreases clearance bacteria from intestine. this due to motor dysfunction gut, autonomic diabetic polyneuropathy, portal hypertension, decrease motor-stimulating influence thyroid hormones. In including MAFLD, association was found between severity Further work effect eradication condition prognosis various required.

Language: Английский

Citations

46
Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets DOI Creative Commons
Xinyu Li, Maozhang He,

Xinrui Yi

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(5), P. e26991 - e26991

Published: Feb. 27, 2024

Nonalcoholic fatty liver disease (NAFLD) is a stress-induced injury related to heredity, environmental exposure and the gut microbiome metabolism. Short-chain acids (SCFAs), metabolites of microbiota (GM), participate in regulation hepatic steatosis inflammation through gut-liver axis, which play an important role alleviation NAFLD. However, little progress has been made systematically elucidating mechanism how SCFAs improve NAFLD, especially epigenetic mechanisms potential therapeutic application as clinical treatment for Herein, we adopted PubMed Medline search relevant keywords such 'SCFAs', 'NAFLD', 'gut microbiota', 'Epigenetic', 'diet', 'prebiotic effect' review latest research on NAFLD up November 2023. In this review, firstly, specifically discussed production function SCFAs, well their crosstalk coordination axis. Secondly, provided updated summary intensive discussion affect alleviate from perspective genetic epigenetic. Thirdly, paid attention pharmacological physiological characteristics proposed promising future direction adopt alone or combination with prebiotics drugs prevent treat Together, aimed elucidate provide new insights prospects target

Language: Английский

Citations

16
Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update DOI Open Access

Júlia Pauli De Cól,

Enzo Pereira de Lima,

Fernanda Moris Pompeu

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(7), P. 3694 - 3694

Published: March 26, 2024

Metabolic-associated fatty liver disease (MAFLD) includes several metabolic dysfunctions caused by dysregulation in the brain–gut–liver axis and, consequently, increases cardiovascular risks and dysfunction. In MAFLD, type 2 diabetes mellitus, obesity, syndrome are frequently present; these conditions related to lipogenesis systemic inflammation. This study aimed review connection between MAFLD. The inflammatory process, cellular alterations hepatocytes stellate cells, hypercaloric diet, sedentarism aggravate prognosis of patients with Thus, understand modulation physiopathology it is necessary include organokines involved this process (adipokines, myokines, osteokines, hepatokines) their clinical relevance project future perspectives condition bring light new possibilities therapeutic approaches. Adipokines responsible for activation distinct signaling different tissues, such as insulin pro-inflammatory cytokines, which important balancing substances avoid MAFLD its progression. Myokines improve quantity quality adipose contributing avoiding development Finally, hepatokines decisive improving or not progression through regulation anti-inflammatory organokines.

Language: Английский

Citations

15
Adipose-derived extracellular vesicles – a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome DOI
Dušan Mladenović, Milena Vesković, Nikola Šutulović

et al.

Endocrine, Journal Year: 2024, Volume and Issue: 85(1), P. 18 - 34

Published: Jan. 29, 2024

Language: Английский

Citations

14
Nutrition at the Intersection between Gut Microbiota Eubiosis and Effective Management of Type 2 Diabetes DOI Open Access
Sevag Hamamah,

Oana C. Iatcu,

Mihai Covașă

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(2), P. 269 - 269

Published: Jan. 16, 2024

Nutrition is one of the most influential environmental factors in both taxonomical shifts gut microbiota as well development type 2 diabetes mellitus (T2DM). Emerging evidence has shown that effects nutrition on these parameters not mutually exclusive and changes related metabolites such short-chain fatty acids (SCFAs) branched-chain amino (BCAAs) may influence systemic inflammation signaling pathways contribute to pathophysiological processes associated with T2DM. With this background, our review highlights macronutrients, carbohydrates, proteins, lipids, micronutrients, vitamins, minerals, T2DM, specifically through their alterations they produce. Additionally, we describe influences common food groups, which incorporate varying combinations macronutrients metabolic context mellitus. Overall, first line modifiable therapies management T2DM a better understanding mechanisms by its pathophysiology provides opportunities for optimizing dietary interventions.

Language: Английский

Citations

11
Bacteroides and NAFLD: pathophysiology and therapy DOI Creative Commons
Jun Zhang, Jing Zhou,

Zheyun He

et al.

Frontiers in Microbiology, Journal Year: 2024, Volume and Issue: 15

Published: March 20, 2024

Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic condition observed globally, with the potential to progress non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma. Currently, US Food Drug Administration (FDA) has not approved any drugs for treatment of NAFLD. NAFLD characterized by histopathological abnormalities in liver, such as lipid accumulation, steatosis, hepatic balloon degeneration, inflammation. Dysbiosis gut microbiota its metabolites significantly contribute initiation advancement Bacteroides , probiotic, shown strong preventing onset progression However, precise mechanism which treats remains uncertain. In this review, we explore current understanding role NAFLD, focusing on their ability reduce inflammation, mitigate enhance intestinal barrier function. Additionally, summarize how alleviates pathological changes restoring metabolism, improving insulin resistance, regulating cytokines, promoting tight-junctions. A deeper comprehension mechanisms through involved pathogenesis should aid development innovative targeting

Language: Английский

Citations

11
Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact DOI
Anna Alisi, Geoffrey W. McCaughan, Henning Grønbæk

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 861 - 872

Published: July 12, 2024

Language: Английский

Citations

10
Interactions between Gut Microbiota and Natural Bioactive Polysaccharides in Metabolic Diseases: Review DOI Open Access
Yu Pi,

Miaoyu Fang,

Yanpin Li

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(17), P. 2838 - 2838

Published: Aug. 24, 2024

The gut microbiota constitutes a complex ecosystem, comprising trillions of microbes that have co-evolved with their host over hundreds millions years. Over the past decade, growing body knowledge has underscored intricate connections among diet, microbiota, and human health. Bioactive polysaccharides (BPs) from natural sources like medicinal plants, seaweeds, fungi diverse biological functions including antioxidant, immunoregulatory, metabolic activities. Their effects are closely tied to which metabolizes BPs into health-influencing compounds. Understanding how interact is critical for harnessing potential health benefits. This review provides an overview focusing on its role in diseases obesity, type II diabetes mellitus, non-alcoholic fatty liver disease, cardiovascular diseases. It explores basic characteristics several impact microbiota. Given significance health, we summarize these BPs, particularly terms immunoregulatory activities, blood sugar, hypolipidemic effect, thus providing valuable reference understanding benefits treating These properties make promising agents preventing comprehensive mechanisms by exert through opens new avenues developing targeted therapies improve

Language: Английский

Citations

9
Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice DOI

Weiting Hu,

Wenyu Gong,

Fan Yang

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 147, P. 113937 - 113937

Published: Jan. 2, 2025

Language: Английский

Citations

1
Thyme, oregano, and rosemary: herbs and food supplements for the management of metabolic associated fatty liver disease DOI
Hamza Elbouny, Ayoub Amssayef,

Rania Benjamaa

et al.

Nutrire, Journal Year: 2025, Volume and Issue: 50(1)

Published: Jan. 6, 2025

Language: Английский

Citations

1